Sangamo Therapeutics to Regain Full Rights to Hemophilia A …
Dec 30, 2024 · These risks and uncertainties are described more fully in Sangamo’s Securities and Exchange Commission, or SEC, filings and reports, including in Sangamo’s Annual Report on Form 10-K for the year ended December 31, 2023, as supplemented by Sangamo’s Quarterly Report on Form 10-Q for the quarter ended September 30, 2024, and subsequent ...
Sangamo Therapeutics Stock Plunges As Pfizer Terminates …
Dec 31, 2024 · On Monday, Sangamo Therapeutics, Inc. (NASDAQ: SGMO) regained the development and commercialization rights to giroctocogene fitelparvovec, an investigational gene therapy product candidate for...
Sangamo shares plunge after Pfizer ends hemophilia A gene …
Dec 30, 2024 · Sangamo Therapeutics said on Monday that partner Pfizer has terminated their hemophilia A gene therapy co-development agreement, sending its shares down nearly 64% in extended trade.
Sangamo Plunges After Pfizer Ends Pact for Hemophilia Drug
Dec 30, 2024 · The stock had quadrupled this year before Sangamo disclosed Pfizer’s decision. ... The company’s market value was just below $500 million before the Pfizer news hit.
Pfizer Ends Sangamo Alliance With Gene Therapy for Hemophilia …
Dec 31, 2024 · Pfizer is walking away from partner Sangamo Therapeutics ahead of expected regulatory submissions for the hemophilia A gene therapy they co-developed. Cash-strapped Sangamo said it is now looking ...
Sangamo Therapeutics to Regain Full Rights to Hemophilia A …
RICHMOND, Calif., December 30, 2024--SANGAMO THERAPEUTICS TO REGAIN FULL RIGHTS TO HEMOPHILIA A GENE THERAPY PROGRAM FOLLOWING PFIZER’S DECISION TO CEASE DEVELOPMENT
Sangamo’s stock sinks 50% as Pfizer halts haemophilia A gene …
Dec 31, 2024 · Sangamo Therapeutics’ stock has plummeted by 50% in premarket trading after Pfizer ended the companies’ partnership to co-develop a gene therapy for haemophilia A. Sangamo announced it will regain the development and commercialisation rights to giroctocogene fitelparvovec, an investigational gene therapy for adults with moderately severe to ...
Pfizer Ends Sangamo Partnership for Hemophilia Therapy
Dec 30, 2024 · Sangamo and Pfizer together developed the treatment, called giroctocogene fitelparvovec, and it was licensed to Pfizer. ... Dow Jones Newswires is a market-moving financial and business news ...
Pfizer drops hemophilia gene therapy, imperiling partner Sangamo …
Dec 30, 2024 · Pfizer has abandoned development of a hemophilia A gene therapy it licensed from Sangamo Therapeutics, a move that could imperil Sangamo’s future.
Sangamo Plunges After Pfizer Ends Pact for Hemophilia Drug
Dec 30, 2024 · Sangamo Therapeutics Inc. shares fell the most in 16 years after Pfizer Inc. ended the two companies’ partnership to develop a new gene therapy to treat hemophilia A.